Thus, targeting αCD40 specifically to B cells could help circumvent the upregulation of CD11b while still inducing B cell activation and expression of Lta. In line with this, a recent study reported that systemic administration of 4-1BBL+ B cells activated in vitro with αCD40 and IFNγ elicited anti-tumor immunity in glioma-bearing mice46. Here, IFNG is linked to neoplasm.